Table 1

AI4 T cell–induced diabetes in NOD.IFN-γnull mice is blocked by coinfusing recipients with splenocytes from standard NOD mice individually lacking T or B cells, but not both lymphocyte subtypes

Source of splenocytes coinjected with 1 × 107 NOD.Rag1null.AI4 splenocytes into NOD.IFN-γnull recipients*Fraction diabeticPercent diabeticχ2P value
NOD.IFN-γnull25/25100
NOD0/100<0.001
NOD.IgHnull0/50<0.001
NOD.TCRαnull1/520<0.001
NOD.CD8null0/50<0.001
NOD CD8-depleted0/40<0.001
NOD CD4-depleted0/40<0.001
NOD CD8- and CD4-depleted0/40<0.001
NOD CD8-, CD4-, and B cell–depleted8/10800.05 > P > 0.02
NOD.Rag1null5/5100NS
NOD.scid9/1090NS
  • *Recipients were monitored for diabetes development for 3 weeks after adoptive transfer of splenocytes.

  • P values from χ2 analyses comparing the frequency of diabetes between AI4 splenocyte–infused NOD.IFN-γnull mice coinjected with NOD.IFN-γnull splenocytes and splenocytes from other sources.